JAC Advance Access published online on April 25, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg244
© 2003 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 Laboratory of Molecular
Immunology of Infection and Inflammation, Pasteur Institute of Lille,
1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex
* Corresponding author. E-mail: georges.bahr{at}pasteur-lille.fr.
Received 27 November 2002
; revised 26 February 2003
; accepted 7 March 2003
In an effort to evaluate the potential of non-specific
immunotherapy in restoring global immunity, we have examined the
clinical tolerance and biological effects of a 6 week administration
of the immunomodulator, murabutide, in chronically infected HIV-1
patients. Forty-two subjects, presenting weak immune reconstitution
and ineffective virus suppression following long-term highly active
antiretroviral therapy (HAART), were randomized to receive, or not,
murabutide 7 mg/day on five consecutive days/week. Clinical
and immunological parameters were monitored before and after the
immunotherapy period. Administration of murabutide was generally
well tolerated, although some grade III adverse events, reversible
on treatment cessation, were observed. Interestingly, in comparison
with pre-inclusion levels, at 1 week after the immunotherapy cycle,
only murabutide recipients presented a significant increase in CD4
cells, platelet counts, and in the percentage of patients with undetectable
viral loads (<50 copies/mL). Statistical significance between
the two groups was only evident with the latter parameter. Some
of these clinical changes were maintained even up to 12 weeks after
murabutide administration, and were accompanied by an increased
ability to mount cellular responses to active immunization with
a recall antigen, and by a significant increase in the percentage
of patients presenting positive lymphoproliferative responses to
the viral antigen gp160. These results warrant further evaluation
of extended periods or cycles of murabutide immunotherapy as adjunct
to HAART.
Keywords: HIV, immunotherapy, murabutide, lymphoproliferation,
chemokines
Clinical and immunological effects of a 6 week
immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful
long-term antiretroviral treatment
2 Department of Infectious Diseases,
Northern AIDS Reference Center, Tourcoing Hospital, Tourcoing
3 Department of Virology, Lille University
Hospital Center, Lille, France
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. C. Zink, J. Uhrlaub, J. DeWitt, T. Voelker, B. Bullock, J. Mankowski, P. Tarwater, J. Clements, and S. Barber Neuroprotective and Anti-Human Immunodeficiency Virus Activity of Minocycline JAMA, April 27, 2005; 293(16): 2003 - 2011. [Abstract] [Full Text] [PDF]
|
|